In this paper, we discovered that ZnFe(2)O(4) magnetic nanoparticles (MNPs) possess intrinsic peroxidase-like activity. ZnFe(2)O(4) MNPs exhibit several advantages such as high catalytic efficiency, good stability, monodispersion, and rapid separation over other peroxidase nanomimetics and horseradish peroxidase (HRP). ZnFe(2)O(4) MNPs were used as a colorimetric biosensor for the detection of urine glucose. This method is simple, inexpensive, highly sensitive, and selective for glucose detection using glucose oxidase (GOx) and ZnFe(2)O(4) MNPs with a linear range from 1.25 × 10(-6) to 1.875 × 10(-5) mol L(-1) with a detection limit of 3.0 × 10(-7) mol L(-1). The color change observable by the naked eyes based on the oxidation of 3,3',5,5'-tetramethylbenzidine (TMB) is the principle for the sensing of urine glucose level.

AIMSPropranolol may have shown excellent results as a first line therapy in infantile haemangiomas (IHs) at all sites in the body, but this conclusion remains controversial. In an attempt to resolve this issue, we performed a meta-analysis. METHODSA search of the literature using PubMed, MEDLINE, Cochrane Library databases and China National Knowledge Infrastructure (CNKI) was performed to identify studies which estimated the efficacy of propranolol therapy in infants with haemangiomas all sites of the body. The pooled odds ratio (OR) along with the corresponding 95% confidence intervals (CI) were assessed using a fixed effects model. RESULTSThirty-five studies involving 324 infantile haemangioma(IH) patients and 248 controls were retrieved and analyzed. The efficacy of propranolol was greater than other therapies in treating IHs (OR = 9.67, 95% CI 6.62, 14.12, P < 0.001). In a stratified analysis by sites of tumour, propranolol was a more effective therapy when compared with steroids (OR = 9.67, 95% CI 6.61, 14.15, P < 0.001), vincristine (OR = 9.00, 95% CI 2.15, 37.66, P = 0.003) and laser treatment (OR = 9.00, 95% CI 1.42, 57.12, P = 0.020) in treating cutaneous IHs (OR = 24.95, 95% CI 9.48, 65.64, P < 0.001), peri-ocular IHs (OR = 9.39, 95% CI 3.88, 22.71, P < 0.001), infantile airway haemangiomas (OR = 20.91, 95% CI 7.81, 55.96, P < 0.001) and infantile hepatic haemangiomas (OR = 9.89, 95% CI 1.20, 81.54, P = 0.033). CONCLUSIONThe current meta-analysis provided strong evidence for propranolol as a first line therapy for IHs. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Propranolol has shown excellent results in treating infantile hemangiomas of all sites of the body, but this conclusion remains controversial. WHAT THIS STUDY ADDS• This meta-analysis has provided strong evidence that propranolol is better than other treatment modalities for the resolution of infantile hemangiomas of all sites of the body for the first time.

Metal−support interactions are of great importance in determining the support-activity in heterogeneous catalysis. Here we report a low-temperature synthetic strategy to create atomically dispersed palladium atoms anchored on defective hexagonal boron nitride (h-BN) nanosheet. Density functional theory (DFT) calculations suggest that the nitrogencontaining B vacancy can provide stable anchoring sites for palladium atoms. The presence of single palladium atoms was confirmed by spherical aberration correction electron microscopy and extended X-ray absorption fine structure measurement. This catalyst showed exceptional efficiency in chemoselective hydrogenation of cinnamaldehyde, along with excellent recyclability, sintering-resistant ability, and scalability. We anticipate this synthetic approach for the synthesis of high-quality SACs based on h-BN support is amenable to large-scale production of bench-stable catalysts with maximum atom efficiency for industrial applications.

Two novel Eu metal-organic frameworks (MOFs), namely {[Eu(pdba)(HO)]·2HO} (1) and {[Eu(pdba)(HO)]·5HO} (2), were prepared with 4'-(1H-pyrazol-3-yl)-[1,1'-biphenyl]-3,5-dicarboxylic acid (Hpdba) under hydrothermal conditions. MOF 1 exhibits a 3D supramolecular structure assembled from the ππ interactions between the benzene rings of the ligands, whereas 2 comprises a 3D structure through coordination connection between nitrogen atom and Eu. It is worth noting that the two MOFs showed good luminescence performance and high-sensitivity fluorescence quenching behavior toward Fe (Cr) and nitrobenzene. Furthermore, the experimental results for stability in water and cycle test show that these two MOFs can be used as potential fluorescent probes.

Purpose Neuropathic pain is an unavoidable treatment-related adverse event among patients with head and neck cancer who are undergoing radiotherapy. We aimed to test the efficacy and safety of pregabalin versus placebo in the treatment of radiotherapy-related neuropathic pain. Patients and Methods This randomized, double-blind, placebo-controlled trial was conducted in four centers in China. Eligible patients with a mean pain intensity score of 4 or more on an 11-point numeric rating scale were randomly assigned to receive either active treatment with a flexible dose of pregabalin or placebo for 16 weeks. The primary efficacy outcome was pain reduction measured on the numeric rating scale. Result There were 128 patients who received treatment as randomly assigned. Pain intensity reduction was 2.44 in the pregabalin arm and 1.58 in the placebo arm at week 16, yielding an adjusted mean difference of 0.87 (95% CI, 0.30 to 1.44; P = .003). In the pregabalin arm, 38 patients (59.4%) achieved at least 30% pain relief versus 21 (32.8%) in the placebo arm ( P = .006). Nineteen patients (29.7%) in the pregabalin group and five (7.8%) in the placebo group achieved 50% or greater pain relief ( P = .003). Total scores on the Profile of Mood States-Short Form, pain severity and functional interference of Brief Pain Inventory-Short Form, as well as the physiology and psychology domain of the WHO Quality of Life-BREF all were reduced significantly at week 16 in patients who received pregabalin compared with those who received placebo. There was no significant difference ( P = .29) in the incidence of experiencing at least one adverse event in the pregabalin arm (n = 35; 54.7%) versus the placebo arm (n = 29; 45.3%). Conclusion Patients treated with pregabalin with radiotherapy-related neuropathic pain had greater pain alleviation, better mood states, and higher quality of life compared with patients in the placebo group, with a good tolerability.